Deciphering the pathogenic role of a variant with uncertain significance for short QT and Brugada syndromes using gene-edited human-induced pluripotent stem cell-derived cardiomyocytes and preclinical drug screening by El-Battrawy, I. et al.
Received: 11 September 2021 Revised: 24 October 2021 Accepted: 30 October 2021
DOI: 10.1002/ctm2.646
LETTER TO EDITOR
Deciphering the pathogenic role of a variant with uncertain
significance for short QT and Brugada syndromes using
gene-edited human-induced pluripotent stem cell-derived
cardiomyocytes and preclinical drug screening
Dear Editor,
In the present study, we show that the Calcium Voltage-
Gated Channel Auxiliary Subunit Beta 2 (CACNB2) vari-
ant c.1439C>T/p.S480L is linked to the clinical phenotype
of short QT syndrome 5 (SQTS5) overlapped with Brugada
syndrome (BrS). The PI3K pathway may contribute to the
arrhythmogenesis of the disease. PI3K-activator and amio-
darone but not sotalol may be effective drugs for treating
arrhythmias in SQTS5-patients carrying but not limited to
this variant.
The SQTS is characterized by a shortening of the cor-
rected QT (QTc) interval, which has been linked to sudden
cardiac death.1,2 Implantable cardioverter-defibrillator
therapy is associated with numerous complications.3
Therefore, drug therapy is important to optimize the treat-
ment of SQTS patients. Recently published data have
reported that hydroquinidine is effective in prolonging the
QTc interval in SQTS patients. Notably, data have shown
that hydroquinidine might exert different effects depend-
ing on the genetic variant and/or SQTS form.4,5
Based on the limited evidence of the clear role of vari-
ants in calcium channel subunits in SQTS and the absence
of alternative therapies in this rare cohort,6 we aimed to
use cardiomyocytes from induced pluripotent stem cells
(hiPSC-CMs) derived from a SQTS5-patient overlapped
with BrS carrying a variant in CACNB2 to study the signif-
icance of the variant for the clinical phenotype by combin-
ing gene editing and electrophysiological analysis in order
to identify possible effective drugs for the disease. HiPSC-
CMs offered advantages over other models to model chan-
nelopathies in the dish.7,8
For this study, human iPSC lines from one SQTS patient,
from two healthy donors, and two Clustered Regularly
Interspaced Short Palindromic Repeats (CRISPR)/Cas9
gene-edited hiPSC lines were used (Figure S1A,B). The
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hiPSC lines were verified for pluripotency (Figure S1C–E)
and were differentiated into cardiomyocytes (Figure S1F),
showing cardiac action potential (AP) features (Figure S2).
The SQTS patient showed an abbreviated QTc interval
with a QTc of 330 ms (Figure 1A) and was admitted
due to an aborted cardiac arrest. A genetic screening
of SQTS related genes of this patient detected a vari-
ant, namely c.1439C>T/p.S480L (dbSNP rs121917812;
Clinvar RCV000010155.3; NM_000724.4: c.1439C>T;
NM_201590.3: c.1442C>T) in CACNB2, a beta-subunit of
L-type calcium channel (Figure 1C). Sequencing of SQTS
related genes confirmed the existence of the same variant
in other first or second-degree relatives (Figure 1B,C) with
a SQTS and BrS phenotype.
The durations of AP at 50% (APD50) and 90% repolar-
ization (APD90) were significantly shorter in SQTS5 cells
compared to that in the cells from the healthy donor and
isogenic control cells (Figure 1D–F). The maximal depo-
larization speed (Vmax) of APs was decreased (Figure 1G).
Of note, the APD-shortening remained at all the tested fre-
quencies. In addition, HD-MEA recordings detected that
the field potential duration in SQTS5-hiPSC-CMs was also
significantly shorter compared to the healthy or isogenic
control (Figure 1H–I). In recordings of spontaneous APs,
the frequency of cell beating in SQTS5-hiPSC-CMswas sig-
nificantly slower than that in healthy cells, without dif-
ference inmaximal diastolic potential (Figure S3C,D,G,H).
After the APD parameters were corrected for beating fre-
quency (Bazettťs correction), the correctedAPDswere also
shorter in SQTS5-hiPSC-CMs (Figure S3C–F).
The L-type calcium channel current (ICa-L) was signif-
icantly decreased in SQTS5-hiPSC-CMs as compared to
that from the healthy control and isogenic control (Fig-
ure 2A,B). The activation curve of ICa-L in SQTS5-cells
was shifted to more positive potentials compared with that
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F IGURE 1 Clinical and biological characteristics of the short QT syndrome 5 (SQTS5) patient. (A) electrocardiogram (ECG) presenting
corrected QT (QTc) abbreviation (QTc = 330 ms, QT 330 ms at heart rate 60 beats per min). (B) Family pedigree of the SQTS5-patient. The
patient recruited for this study is indicated by the arrow. (C) Scheme of the CaVα1C- and CaVβ2-subunits showing that the α-interacting
domain (AID) binds to the β-subunit guanylate kinase domain (GK). The variant S480L in CaVβ2 might interfere proper interaction of the
subunits. (D–G) Action potentials paced at 1 to 3 Hz were recorded by patch-clamp techniques and the duration at 50% (APD50) and 90%
(APD90), as well as the maximal velocity of depolarization (Vmax), were compared among cardiomyocytes from induced pluripotent stem cells
(hiPSC-CMs) from the SQTS5-patient (SQTS5), the healthy donor (Healthy) and CRISPR-corrected SQTS5 (Corrected) cells. (D)
Representative action potential (AP) traces of cells from each cell line at 1 Hz. (E) Averaged values of APD50 in each cell line at 1–3 Hz. (F)
Averaged values of APD90 in each cell line at 1–3 Hz. (G) Averaged values of Vmax in each cell line at 1–3 Hz. (H) Representative traces of field
potentials in cells of each cell line. (I) Averaged values of field potential duration (FPD) in each cell line. “n” numbers represent the number
of cells. *p < .05 versus Healthy according to the analysis of one-way ANOVA with Holm-Sidak post-test.
in isogenic control hiPSC-CMs. Besides, the inactivation
curve shifted to more negative potentials, and recovery
from inactivation decelerated in SQTS5-hiPSC-CMs com-
pared with both healthy and isogenic control cells (Fig-
ure 2C–H). Western blot and immunostaining analyses
detected that the protein expression level of CACNB2 was
significantly decreased in SQTS5-hiPSC-CMs (Figure S4).
The alpha subunit of L-type Ca2+ channel CACNA1C was
slightly increased in cell lysates (Figure S4) but not in the
cell membrane (Figure S4).
Since loss-of-function of the sodium channel is a main
feature of BrS, the peak sodium channel current (INa)
and their kinetics were assessed (Figure 3A,B and Fig-
ure S5A–F). In SQTS5-hiPSC-CMs, the peak INa and acti-
vation were significantly suppressed compared to healthy
cells.
To test the arrhythmogenicity of hiPSC-CMs of the
SQTS5-patient, spontaneous calcium transients and spon-
taneous APs were recorded. Compared to healthy donor
and isogenic control cells, a higher number of SQTS5-cells
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F IGURE 2 L-type calcium channel current decreased in SQTS5-hiPSC-CMs. For analyzing the current amplitude and activation of
L-type calcium channels, the protocol indicated in (A) (inset) was used. For analyzing inactivation and recovery from inactivation of L-type
calcium channels, protocols indicated in (E) (inset) and (G) (inset) were used, respectively. (A) Representative current traces in
cardiomyocytes from induced pluripotent stem cells (hiPSC-CMs) from the patient (short QT syndrome 5 [SQTS5]), the healthy donor
(Healthy), and the CRISPR-corrected (Corrected) cells. (B) The current-voltage (I-V) relationship curves of L-type calcium channel currents
(ICa-L) in cells from each group. (C) The activation curves of ICa-L in cells from each group. (D) The half-maximum activation potential (V0.5) of
ICa-L in cells from each group. (E) The inactivation curves of ICa-L in cells from each group. (F) The half-maximum inactivation potential
(V0.5) of ICa-L in cells from each group. (G) The curves of recovery from inactivation of ICa-L in cells from each group. (H) The time constants
(τ) of recovery from inactivation of ICa-L in cells from each group. “n” numbers represent the number of cells. *p < .05 versus Healthy
according to the analysis of one way analysis of variance (ANOVA) with Holm-Sidak post-test
displayed arrhythmic events (irregular or triggered beats)
(Figure 3C–F). The interval variability (standard deviation
of beating intervals) in SQTS5-hiPSC-CMs was larger than
that in donor and isogenic control cells (Figure 3C–F).
For details about methods, please see Supporting Infor-
mation. As expected, insertion of the present CACNB2
variant using CRISPR/Cas 9 in a further control cell line
(Figure S6) led to a loss-of-function of ICa-L and an APD-
shortening with a reduction of Vmax (Figure S7).
Quinidine and amiodarone prolonged APD (Fig-
ures S8 and S9) but only amiodarone showed a sig-
nificant antiarrhythmic effect (Figure S9). Sotalol
showed no effect in SQTS5-cells although it pro-
longed APD in healthy cells (Figures S10 and
S11).
Since the PI3Kpathwaymay influence ion channel func-
tion and QT interval,9,10 we measured the protein levels of
PI3K andAkt. Both total and phosphorylation levels of Akt
and PI3K were decreased in SQTS5-hiPSC-CMs compared
to healthy cardiomyocytes (Figure 4A–C).Whereas a PI3K-
activator (IGF-1, 100 ng/ml) reduced the interval variabil-
ity and arrhythmic events, a PI3K blocker (alpelisib, 5
μM) enhanced both (Figure 4D–F). In addition, the PI3K-
activator prolonged the APD (Figure 4G,H).
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F IGURE 3 Peak sodium channel current decreased in SQTS5-hiPSC-CMs and arrhythmic events were increased. For analyzing the
current amplitude and activation of sodium channels, the protocol indicated in (A) (inset) was used. For analyzing inactivation and recovery
from inactivation, protocols indicated in S5C (inset) and S5E (inset) were used, respectively. (A) Representative current traces in
cardiomyocytes from induced pluripotent stem cells (hiPSC-CMs) from the patient (short QT syndrome 5 [SQTS5]), the healthy donor
(Healthy), and the CRISPR-corrected (Corrected) cells. (B) The current-voltage (I-V) relationship curves of sodium channel currents (INa) in
cells from each group. Spontaneous calcium transients and action potentials were recorded in spontaneously beating hiPSC-CMs from the
patient (SQTS5), the healthy donor (Healthy), and the CRISPR-corrected cells (Corrected). The occurrence of arrhythmic events (irregular or
triggered beats or EAD-like events) was compared among the three cell groups. (C) Representative traces of calcium transients in cells from
each line. Arrhythmic events are marked by arrows (black, EAD-like events; red, triggered beats). (D) Representative traces of spontaneous
action potentials in cells from the healthy donor (Healthy) and the patient (SQTS5), showing trigeminus-like arrhythmic events in
SQTS5-hiPSC-CMs. (E) Percentage of cells showing arrhythmic events. The numbers given represent the number of cells. *p < .05 versus
Healthy according to the Fisher-test. (F) The standard deviation of cell beat intervals in SQTS5-hiPSC-CMs, healthy donor and isogenic
control cells. “n” numbers represent the number of cells. *p < .05 versus Healthy according to the analysis of one way analysis of variance
(ANOVA) with Holm-Sidak post-test
In conclusion, the variant c.1439C>T/p.S480L in the
CACNB2 gene is responsible for phenotypic changes
of SQTS5 overlapping with BrS. Amiodarone reduces
arrhythmic events in the dish and based on this, we may
assume that it may be clinically more effective than quini-
dine for treating SQTS5 and /or BrS. The PI3K/Akt activity
can be reduced in SQTS5 and an activator of this signaling
pathway may rescue the phenotype.
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F IGURE 4 PI3 signaling was altered in SQTS5-hiPSC-CMs. (A) Representative bands of western blots showing the expression levels of
phosphorylated Akt (p-Akt) and PI3K (p-PI3K) or total Akt (Akt) and PI3K (PI3K). (B) Mean values of phosphorylated and total Akt protein
levels normalized to that of healthy cells. (C) Mean values of phosphorylated and total PI3K protein levels normalized to that of healthy cells.
“n” represents the number of experiments. (D) Interval variability in the absence (Ctr) and presence of a PI3K inhibitor alpelisib (PI3K inh.)
or PI3K activator IGF-1 (PI3K act.). (E) Percentage of cells showing arrhythmic events in the absence (Ctr) and presence of alpelisib (PI3K
inh.) or IGF-1 (PI3K act.). “n” represents the number of cells. (F) Representative traces of calcium transients in an SQTS5-hiPSC-CM in the
absence (short QT syndrome 5 [SQTS5]) and presence of alpelisib (PI3K inh.) or IGF-1 (PI3K act.). (G) Mean values of action potential
duration at 50% repolarization (APD50) in the absence (SQTS5, Healthy) and presence of IGF-1 (SQTS5 + PI3K act. and Healthy + PI3K act.)
(H) Mean values of action potential duration at 90% repolarization (APD90) in the absence (SQTS5, Healthy) and presence of IGF-1 (SQTS5 +
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